Forest Laboratories's revenue per share for the
three
months ended in Mar. 2014 was €2.83.
Forest Laboratories's revenue per share for the trailing twelve months (TTM) ended in Mar. 2014 was €9.89.
Warning Sign:
Forest Laboratories Inc revenue has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Forest Laboratories was 14.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -4.20% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -3.30% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 5.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Forest Laboratories's Revenue per Share or its related term are showing as below:
FRA:FQX'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -5.6 Med: 13.2 Max: 44.6
Current: -4.2
During the past 13 years, Forest Laboratories's highest 3-Year average Revenue Per Share Growth Rate was 44.60% per year. The lowest was -5.60% per year. And the median was 13.20% per year.
FRA:FQX's 3-Year Revenue Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 6.5
vs FRA:FQX: -4.20
Forest Laboratories Revenue per Share Historical Data
The historical data trend for Forest Laboratories's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Forest Laboratories's Revenue per Share
For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forest Laboratories's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's PS Ratio distribution charts can be found below:
* The bar in red indicates where Forest Laboratories's PS Ratio falls into.
Forest Laboratories Revenue per Share Calculation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Forest Laboratories's Revenue Per Share for the fiscal year that ended in Mar. 2014 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €9.89
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forest Laboratories (FRA:FQX) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Forest Laboratories Revenue per Share Related Terms
Thank you for viewing the detailed overview of Forest Laboratories's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Forest Laboratories (FRA:FQX) Business Description
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:FQX has been successfully added to your 